Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Yoo BW, Kim CO, Izu A, Arora AK, Heijnen E. Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years. Infect Chemother 2018;50:301-310. [PMID: 30600653 PMCID: PMC6312896 DOI: 10.3947/ic.2018.50.4.301] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Accepted: 09/23/2018] [Indexed: 01/25/2023] Open

For:	Yoo BW, Kim CO, Izu A, Arora AK, Heijnen E. Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD® and VANTAFLU® in South Korean Subjects Aged ≥65 Years. Infect Chemother 2018;50:301-310. [PMID: 30600653 PMCID: PMC6312896 DOI: 10.3947/ic.2018.50.4.301] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Accepted: 09/23/2018] [Indexed: 01/25/2023] Open

Number

Cited by Other Article(s)

Dos Santos G, Devadiga R, Kim CS, Bang J. An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older. Drug Saf 2024;47:365-375. [PMID: 38483767 PMCID: PMC10955014 DOI: 10.1007/s40264-024-01395-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/09/2024] [Indexed: 03/21/2024]

Amicizia D, Domnich A, Lai PL, Orsi A, Icardi G, Tkach-Motulyak O, Panatto D. Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season. Hum Vaccin Immunother 2023;19:2190279. [PMID: 36919537 PMCID: PMC10072113 DOI: 10.1080/21645515.2023.2190279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023] Open

Wang R, Huang X, Cao T, Sun C, Luo D, Qiu H, Wu M, Huang X, Yu C, Li J, Kong D, Ma J, Zhang X, Hu P, Zhang Y, Luo C, Zhao H, Li Y, Deng Y, Qin C, Xie L. Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants. Virology 2022;576:61-68. [PMID: 36174448 PMCID: PMC9486464 DOI: 10.1016/j.virol.2022.09.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2022] [Revised: 08/23/2022] [Accepted: 09/05/2022] [Indexed: 01/07/2023]

Affiliation(s)

Rui Wang Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China
Xun Huang State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China
Tianshu Cao State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China
Chunyun Sun Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China
Dan Luo State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China
Hongying Qiu State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China
Mei Wu State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China
Xingyao Huang State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China
Chulin Yu Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China
Jing Li Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China
Desheng Kong Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China
Juan Ma Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China
Xiao Zhang Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China
Ping Hu Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China
Yanjing Zhang Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China
Chunxia Luo Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China
Hui Zhao State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China
Yuchang Li State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China
Yongqiang Deng State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China.
Chengfeng Qin State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China.
Liangzhi Xie Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing, 100176, China; Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China.

Collapse

Wang R, Sun C, Ma J, Yu C, Kong D, Chen M, Liu X, Zhao D, Gao S, Kou S, Sun L, Ge Z, Zhao J, Li K, Zhang T, Zhang Y, Luo C, Li X, Wang Y, Xie L. A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. Vaccines (Basel) 2022;10:vaccines10050702. [PMID: 35632456 PMCID: PMC9143086 DOI: 10.3390/vaccines10050702] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 04/13/2022] [Accepted: 04/22/2022] [Indexed: 02/04/2023] Open

Affiliation(s)

Rui Wang Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Chunyun Sun Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Juan Ma Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Chulin Yu Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Desheng Kong Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Meng Chen Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Xuejie Liu Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Dandan Zhao Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Shuman Gao Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Shuyuan Kou Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Lili Sun Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Zeyong Ge Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Jun Zhao Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Kuokuo Li Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Tao Zhang Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Yanjing Zhang Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Chunxia Luo Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Xuefeng Li Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Yang Wang Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.)
Liangzhi Xie Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd., Beijing 100176, China; (R.W.); (C.S.); (J.M.); (C.Y.); (D.K.); (M.C.); (X.L.); (D.Z.); (S.G.); (S.K.); (L.S.); (Z.G.); (J.Z.); (K.L.); (T.Z.); (Y.Z.); (C.L.); (X.L.); (Y.W.) Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100176, China Correspondence: ; Tel.: +86-010-58628378; Fax: +86-010-58628299

Collapse

Chuaychoo B, Kositanont U, Niyomthong P, Rittayamai N, Srisuma S, Rattanasaengloet K, Wongsrisakunkaew W, Thongam J, Songserm T. Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients. Hum Vaccin Immunother 2019;16:1371-1379. [PMID: 31770051 DOI: 10.1080/21645515.2019.1692559] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open